Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 124
interventional 89
Observational 30
Registry 5

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug|placebo 44
Drug 27
Device 7
Other 5
Procedure 3
Device|Drug 1
Diagnostic Test 1
Dietary Supplement|placebo 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 22
China 5
NA 5
Canada 4
Germany 4
United States|Puerto Rico 4
Taiwan 3
France 2
Israel 2
South Africa 2
United States|Austria|Canada|France|Germany|Hungary|Italy|Slovakia|Spain|Switzerland 2
United States|Canada 2
United States|Canada|Puerto Rico 2
Australia|Canada|Finland|France|Germany|Italy|Japan|Spain 1
Austria|Canada|France|Germany|South Africa 1
Belgium|Bulgaria 1
Brazil 1
Canada|United Kingdom 1
Czech Republic|France|Germany|Italy|Serbia|Spain 1
Denmark 1
Germany|Hungary|Portugal|Romania|South Africa|France|United States|Belgium|Bulgaria|Canada|United Kingdom 1
Hong Kong 1
Japan 1
Korea, Republic of 1
Netherlands 1
Poland|United States|Czechia|Germany|Hungary|Slovakia 1
Spain 1
Sweden 1
Sweden|United Kingdom 1
Turkey 1
United States|Australia|Canada|France|Germany|Italy 1
United States|Austria|Canada|France 1
United States|Austria|France|Germany 1
United States|Austria|France|Germany|Spain 1
United States|Canada|Denmark|Germany|Italy|Netherlands|Poland|United Kingdom 1
United States|Canada|Denmark|Israel|Italy|Poland|Russian Federation|Spain|Ukraine|United Kingdom 1
United States|Canada|France|Germany|Hungary|Italy|Spain 1
United States|Canada|Israel|Italy|Korea, Republic of|Spain|Taiwan|United Kingdom 1
United States|Czechia|Germany|Hungary|Poland|Slovakia 1
United States|Czechia|Poland|Slovakia 1
United States|Finland|Greece|Hungary|Italy|Slovakia|Spain 1
United States|France|Germany|Italy 1
United States|Germany|New Zealand 1

Sites per Study

Site_count Study_Count
1 42
2 3
3 1
4 2
5 2
7 1
8 1
11 2
12 1
17 1
19 1
20 2
22 3
24 1
25 1
27 1
28 2
31 1
32 2
33 2
34 1
39 1
41 1
42 1
43 1
46 1
47 1
48 1
51 3
53 1
54 1
70 1
82 2
106 1

Phase

Phase Study_Count
Phase 2 32
N/A 17
Phase 3 17
Phase 4 10
Phase 1 6
Phase 1/Phase 2 4
Phase 2/Phase 3 3

Number of Arms

Number_of_Arms Count_of_Studies
1 11
2 45
3 9
4 5
5 3
6 2
8 1
NA 13

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 8.00000 10.00000 15.00 2.00000 83.0000 40.0000 5.0
1st Qu. 20.00000 12.75000 20.25 29.50000 100.0000 63.0000 34.5
Median 60.00000 22.50000 41.00 68.00000 117.0000 161.0000 64.0
Mean 75.41176 58.33333 40.50 82.46875 146.6667 184.1176 58.6
3rd Qu. 120.00000 32.25000 61.25 103.75000 178.5000 234.0000 83.0
Max. 200.00000 250.00000 65.00 360.00000 240.0000 506.0000 120.0

Trial Group Type

group_type Group_Count
Experimental 115
Placebo Comparator 44
Active Comparator 14
NA 13
Sham Comparator 6
Other 3
No Intervention 1

Intervention Model

intervention_model Study_Count
Parallel Assignment 59
Single Group Assignment 16
Crossover Assignment 11
NA 3

Primary Purpose

primary_purpose Study_Count
Treatment 80
NA 3
Basic Science 2
Diagnostic 1
Other 1
Prevention 1
Supportive Care 1

Observational Studies

Studies by Country

Country Study_Count
United States 11
United States|Canada 4
Turkey 3
United Kingdom 3
France 2
Belgium 1
China 1
Korea, Republic of 1
NA 1
Switzerland 1
Taiwan 1
United States|Denmark|France|Germany 1

Sites per Study

Site_count Study_Count
1 23
2 1
3 1
5 2
6 1
8 1
9 1

Enrollment Metrics

Measure Observational
Min 3.00
1st Qu 36.25
Median 73.00
Mean 266.40
3rd Qu 175.75
Max 4000.00

Observation Model

observational_model Study_Count
Cohort 13
Case-Control 5
Case-Only 3
NA 3
Family-Based 2
Case-Crossover 1
Case Control 1
Natural History 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 14
Cross-Sectional 11
Other 2
Retrospective 2
NA 1

Registries

Studies by Country

Country Study_Count
Canada 1
Egypt 1
Germany 1
Korea, Republic of 1
Switzerland 1

Sites per Study

Site_count Study_Count
1 4
2 1

Enrollment Metrics

Measure Registries
Min 20
1st Qu 30
Median 60
Mean 582
3rd Qu 800
Max 2000

Registry Model

observational_model Study_Count
Cohort 3
Case-Control 1
Family-Based 1

Time Perspective

time_perspective Study_Count
Prospective 3
Cross-Sectional 1
Other 1

Follow-up

target_duration Study_Count
1 Day 1
10 Years 1
20 Years 1
3 Years 1
80 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03368170 Efficacy and Tolerability of IRL790 in Parkinson’s Disease Dyskinesia https://ClinicalTrials.gov/show/NCT03368170 Completed Integrative Research Laboratories AB 2019-06-12
NCT03319485 ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson’s Disease https://ClinicalTrials.gov/show/NCT03319485 Active, not recruiting InSightec 2021-01-31
NCT03270189 Effect of the Visual Information Change in Functional Dystonia https://ClinicalTrials.gov/show/NCT03270189 Recruiting Fondation Ophtalmologique Adolphe de Rothschild 2021-10-31
NCT03252444 Therapeutic Approaches for Subjects With Scapula Dyskinesis https://ClinicalTrials.gov/show/NCT03252444 Completed National Taiwan University Hospital 2017-05-21
NCT03176771 Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT03176771 Active, not recruiting Mitsubishi Tanabe Pharma Corporation 2020-09-30
NCT03120650 Scalp Acupuncture for Dyskinesia After Ischemic Stroke https://ClinicalTrials.gov/show/NCT03120650 Recruiting Shanghai University of Traditional Chinese Medicine 2020-09-20
NCT02871778 Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia https://ClinicalTrials.gov/show/NCT02871778 Completed Parion Sciences 2018-11-20
NCT02799381 A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson’s Disease (DYSCOVER) https://ClinicalTrials.gov/show/NCT02799381 Completed AbbVie 2019-09-19
NCT02736955 Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT02736955 Completed Neurocrine Biosciences 2017-06-30
NCT02657681 Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS) https://ClinicalTrials.gov/show/NCT02657681 Completed Fundación de investigación HM 2018-09-30
NCT02589340 Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia https://ClinicalTrials.gov/show/NCT02589340 Active, not recruiting Oregon Health and Science University 2020-12-31
NCT02198794 Reducing Involuntary Movements in Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT02198794 Active, not recruiting Teva Pharmaceutical Industries 2020-12-31
NCT03704207 Utility of PCD Diagnostics to Improve Clinical Care https://ClinicalTrials.gov/show/NCT03704207 Recruiting Vanderbilt University Medical Center 2020-06-01
NCT02439203 Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia https://ClinicalTrials.gov/show/NCT02439203 Completed Bukwang Pharmaceutical 2015-12-31
NCT02291861 Addressing Involuntary Movements in Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT02291861 Completed Teva Pharmaceutical Industries 2016-08-19
NCT02274766 Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia https://ClinicalTrials.gov/show/NCT02274766 Completed Adamas Pharmaceuticals, Inc. 2016-03-10
NCT02274558 A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT02274558 Completed Neurocrine Biosciences 2015-09-30
NCT02252380 ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders https://ClinicalTrials.gov/show/NCT02252380 Active, not recruiting InSightec 2021-12-31
NCT02195700 Aim to Reduce Movements in Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT02195700 Completed Teva Pharmaceutical Industries 2015-05-31
NCT02136914 ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) https://ClinicalTrials.gov/show/NCT02136914 Completed Adamas Pharmaceuticals, Inc. 2015-12-31
NCT02064010 A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT02064010 Completed Synchroneuron Inc. 2015-01-31
NCT03813238 A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents https://ClinicalTrials.gov/show/NCT03813238 Recruiting Teva Pharmaceutical Industries 2021-09-27
NCT03354455 Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson’s Disease https://ClinicalTrials.gov/show/NCT03354455 Completed Danish Research Centre for Magnetic Resonance 2018-09-16
NCT02003248 A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Pallidotomy in the Treatment of Dyskinesia of Parkinson’s Disease https://ClinicalTrials.gov/show/NCT02003248 Completed Yonsei University 2017-05-16
NCT01937078 Famotidine for Levodopa-induced Dyskinesia in PD https://ClinicalTrials.gov/show/NCT01937078 Completed University Health Network, Toronto 2014-03-31
NCT01804920 D-Serine Treatment For Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT01804920 Active, not recruiting Herzog Hospital 2019-01-31
NCT01767129 Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson’s Disease Patients https://ClinicalTrials.gov/show/NCT01767129 Completed Avanir Pharmaceuticals 2015-02-28
NCT01733121 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT01733121 Completed Neurocrine Biosciences 2013-12-31
NCT01688037 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) https://ClinicalTrials.gov/show/NCT01688037 Completed Neurocrine Biosciences 2013-09-30
NCT01568840 Global Postural Reeducation and Segmental Exercises in Patients With Scapular Dyskinesis and Cervicalgia https://ClinicalTrials.gov/show/NCT01568840 Completed Irmandade da Santa Casa de Misericordia de Sao Paulo 2011-01-31
NCT01563913 Reducing Dyskinesia in Parkinson’s Disease With Omega-3 Fatty Acids https://ClinicalTrials.gov/show/NCT01563913 Completed VA Office of Research and Development 2016-06-30
NCT01543321 Xenazine in Late Dyskinetic Syndrome With Neuroleptics https://ClinicalTrials.gov/show/NCT01543321 Completed Centre Hospitalier Universitaire, Amiens 2017-05-18
NCT01491932 Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias https://ClinicalTrials.gov/show/NCT01491932 Completed Novartis 2013-10-31
NCT01491529 Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias https://ClinicalTrials.gov/show/NCT01491529 Completed Novartis 2013-04-30
NCT01474421 Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson’s Disease https://ClinicalTrials.gov/show/NCT01474421 Completed Novartis 2013-02-21
NCT01397422 Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) https://ClinicalTrials.gov/show/NCT01397422 Completed Adamas Pharmaceuticals, Inc. 2013-05-31
NCT01391390 Melatonin Treatment for Tardive Dyskinesia in Schizophrenia https://ClinicalTrials.gov/show/NCT01391390 Completed Beijing HuiLongGuan Hospital 2011-04-30
NCT01336088 ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson’s Disease https://ClinicalTrials.gov/show/NCT01336088 Completed Addex Pharma S.A. 2012-02-29
NCT04222777 Cervical Spine Motion in the Elderly https://ClinicalTrials.gov/show/NCT04222777 Recruiting Zuyderland Medisch Centrum 2020-03-01
NCT04173845 Double Randomized and Placebo Controlled Trail of Tianqi Pingchan Granule to Prevent Levodopa-Induced Dyskinesia https://ClinicalTrials.gov/show/NCT04173845 Recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 2020-12-31
NCT04173832 Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine https://ClinicalTrials.gov/show/NCT04173832 Recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 2020-12-31
NCT04086160 Effects of Transcranial Direct Current Stimulation (tDCS) on Motor Function in Schizophrenia Patients and Individuals at Risk for Psychotic Onset https://ClinicalTrials.gov/show/NCT04086160 Enrolling by invitation The Hong Kong Polytechnic University 2020-12-31
NCT03956979 A Study in Parkinson’s Disease in paTients With mOderate to seveRe dyskInesiA https://ClinicalTrials.gov/show/NCT03956979 Recruiting Bukwang Pharmaceutical 2021-06-30
NCT03922711 A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson’s Disease https://ClinicalTrials.gov/show/NCT03922711 Recruiting Prilenia 2020-04-30
NCT03891862 Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT03891862 Recruiting Neurocrine Biosciences 2020-09-30
NCT03832491 Effect of Game Based Approach on Oxygenation, Functional Capacity and Quality of Life in Primary Ciliary Dyskinesia https://ClinicalTrials.gov/show/NCT03832491 Recruiting Hacettepe University 2020-03-15
NCT03698331 The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine https://ClinicalTrials.gov/show/NCT03698331 Completed Neurocrine Biosciences 2019-04-03
NCT03531060 A Clinical Study of IRL790 in Patients With Parkinson’s Disease Experiencing Levodopa Induced Dyskinesia https://ClinicalTrials.gov/show/NCT03531060 Completed Integrative Research Laboratories AB 2017-04-12
NCT03495024 Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates https://ClinicalTrials.gov/show/NCT03495024 Recruiting Corporal Michael J. Crescenz VA Medical Center 2020-04-30
NCT01267188 Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT01267188 Completed Neurocrine Biosciences 2011-03-31
NCT01173731 Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias https://ClinicalTrials.gov/show/NCT01173731 Completed Novartis 2013-10-31
NCT01172379 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson’s Disease Patients With “Wearing Off” Motor Fluctuations and “On” Period Dyskinesias https://ClinicalTrials.gov/show/NCT01172379 Completed Eisai Inc. 2005-02-28
NCT01155115 Inflammatory and Microbiologic Markers in Sputum: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia https://ClinicalTrials.gov/show/NCT01155115 Completed The Hospital for Sick Children 2014-12-31
NCT01113320 Safinamide in Levodopa Induced Dyskinesia in Parkinson’s Disease Subjects https://ClinicalTrials.gov/show/NCT01113320 Completed Newron Pharmaceuticals SPA 2011-11-30
NCT01092065 Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson’s Disease Patients With Moderate-severe L-dopa Induced Dyskinesia https://ClinicalTrials.gov/show/NCT01092065 Completed Novartis 2011-07-31
NCT01071395 Validation of Dyskinesia Rating Scales https://ClinicalTrials.gov/show/NCT01071395 Completed Rush University Medical Center 2012-04-30
NCT00986414 Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson’s Disease https://ClinicalTrials.gov/show/NCT00986414 Completed Novartis 2010-12-31
NCT00984100 Natural Orifice Translumenal Endoscopic Surgery (NOTES) Transvaginal Cholecystectomy https://ClinicalTrials.gov/show/NCT00984100 Completed Baystate Medical Center 2015-01-31
NCT00981604 Single Incision Laparoscopic Surgery (SILS) Versus Laparoscopic Cholecystectomy https://ClinicalTrials.gov/show/NCT00981604 Completed Children’s Mercy Hospital Kansas City 2011-08-31
NCT00957918 Study of NP002 in Subjects With Idiopathic Parkinson’s Disease to Treat Dyskinesias Due to Levodopa Therapy https://ClinicalTrials.gov/show/NCT00957918 Completed Neuraltus Pharmaceuticals, Inc. 2010-09-30
NCT00926965 Tardive Dyskinesia and Cognitive Function https://ClinicalTrials.gov/show/NCT00926965 Completed Taipei Veterans General Hospital, Taiwan 2007-12-31
NCT00888186 Different Dyskinesias in Parkinson’s Disease and Their Relation to Levodopa Pharmacokinetics https://ClinicalTrials.gov/show/NCT00888186 Completed Uppsala University 2008-05-31
NCT00888004 Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson’s Disease Patients https://ClinicalTrials.gov/show/NCT00888004 Completed Novartis 2009-08-31
NCT00845000 Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550) https://ClinicalTrials.gov/show/NCT00845000 Completed Merck Sharp & Dohme Corp. 2010-04-30
NCT01393600 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder https://ClinicalTrials.gov/show/NCT01393600 Completed Neurocrine Biosciences 2012-02-29
NCT02405091 Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT02405091 Completed Neurocrine Biosciences 2017-03-31
NCT01385592 Evaluation of the Efficacy and Safety of AFQ056 in Parkinson’s Patients With L-dopa Induced Dyskinesias https://ClinicalTrials.gov/show/NCT01385592 Completed Novartis 2012-09-30
NCT00621998 Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT00621998 Completed Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan 2003-12-31
NCT00582673 Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson’s Disease Patients, and Safety in Combination With L-dopa https://ClinicalTrials.gov/show/NCT00582673 Completed Novartis 2008-05-31
NCT00406029 Dyskinesia in Parkinson’s Disease (Study P04501) https://ClinicalTrials.gov/show/NCT00406029 Completed Merck Sharp & Dohme Corp. 2008-10-05
NCT00401089 Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia https://ClinicalTrials.gov/show/NCT00401089 Completed Lawson Health Research Institute 2006-12-31
NCT00363727 Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson’s https://ClinicalTrials.gov/show/NCT00363727 Completed GlaxoSmithKline 2006-01-31
NCT00360568 Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson’s Subjects https://ClinicalTrials.gov/show/NCT00360568 Completed AbbVie 2012-10-31
NCT00314288 Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia https://ClinicalTrials.gov/show/NCT00314288 Completed EMD Serono NA
NCT00307450 Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson’s Disease https://ClinicalTrials.gov/show/NCT00307450 Completed Technische Universität Dresden 2009-03-31
NCT00291213 Levetiracetam Treatment of Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT00291213 Completed Yale University 2006-04-30
NCT00255879 Movement Disorders Caused by Antipsychotic Drugs in Older Patients https://ClinicalTrials.gov/show/NCT00255879 Completed University of California, San Diego 2004-08-31
NCT00190008 Piracetam for Treatment Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT00190008 Completed Beersheva Mental Health Center NA
NCT00175955 Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT00175955 Completed UCB Pharma 2005-12-31
NCT00164242 Treatment of Tardive Dyskinesia With Galantamine https://ClinicalTrials.gov/show/NCT00164242 Completed Caroff, Stanley N., M.D. NA
NCT00160576 Levetiracetam Treatment in Adult Subjects With Parkinson’s Disease Experiencing Troublesome Dyskinesias https://ClinicalTrials.gov/show/NCT00160576 Completed UCB Pharma 2004-11-30
NCT00114595 Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT00114595 Completed University of Stellenbosch NA
NCT00105521 Sarizotan in Participants With Parkinson’s Disease Suffering From Treatment Associated Dyskinesia https://ClinicalTrials.gov/show/NCT00105521 Completed EMD Serono 2006-03-31
NCT00105508 Sarizotan HC1 in Patients With Parkinson’s Disease Suffering From Treatment-associated Dyskinesia https://ClinicalTrials.gov/show/NCT00105508 Completed EMD Serono 2006-02-28
NCT00086294 ACP-103 to Treat Parkinson’s Disease https://ClinicalTrials.gov/show/NCT00086294 Completed National Institutes of Health Clinical Center (CC) NA
NCT00076674 Levetiracetam Treatment of L-dopa Induced Dyskinesias https://ClinicalTrials.gov/show/NCT00076674 Completed National Institutes of Health Clinical Center (CC) NA
NCT00004576 Study of LY300164 for the Treatment of Parkinson’s Disease https://ClinicalTrials.gov/show/NCT00004576 Completed National Institutes of Health Clinical Center (CC) NA
NCT00036296 Effects of Talampanel on Patients With Advanced Parkinson’s Disease https://ClinicalTrials.gov/show/NCT00036296 Completed Teva Pharmaceutical Industries 2007-02-28
NCT00672373 Extract of Ginkgo Biloba and Tardive Dyskinesia https://ClinicalTrials.gov/show/NCT00672373 Completed Beijing HuiLongGuan Hospital 2007-05-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03370029 Respiratory Muscle Strength, Exercise Capacity and Physical Activity Levels in Children Primary Ciliary Dyskinesia https://ClinicalTrials.gov/show/NCT03370029 Completed Gazi University 2018-02-25
NCT03821740 Kinesiotaping for Normalizing Scapular Dyskinesis https://ClinicalTrials.gov/show/NCT03821740 Completed University of Liege 2019-04-15
NCT03320382 Multiple Breath Washout, a Clinimetric Dataset https://ClinicalTrials.gov/show/NCT03320382 Recruiting Imperial College London 2021-03-31
NCT03256773 High Resolution Micro OCT Imaging https://ClinicalTrials.gov/show/NCT03256773 Recruiting University of Alabama at Birmingham 2020-12-31
NCT02622061 NIOX VERO Nasal Application in Primary Ciliary Dyskinesia https://ClinicalTrials.gov/show/NCT02622061 Completed Aerocrine AB 2016-10-31
NCT02586662 Prediction of Functional Disability in Subjects With Scapular Dyskinesis https://ClinicalTrials.gov/show/NCT02586662 Completed National Taiwan University Hospital 2013-12-31
NCT02389049 Genetics of Primary Ciliary Dyskinesia https://ClinicalTrials.gov/show/NCT02389049 Completed University of North Carolina, Chapel Hill 2018-07-31
NCT01962727 Scapular Dyskinesis: a Reliability and Validity Study of Comprehensive Classification Test https://ClinicalTrials.gov/show/NCT01962727 Completed National Taiwan University Hospital 2012-10-31
NCT01648803 Wearable Movement Sensors for Assessing Motor Impairments and Dyskinesias in Parkinson Disease https://ClinicalTrials.gov/show/NCT01648803 Completed University of Rochester 2013-06-30
NCT01467089 The Assessment of Movement Disorders Utilizing Live Two-Way Video https://ClinicalTrials.gov/show/NCT01467089 Completed Northwell Health 2016-06-30
NCT01429207 Capturing Parkinson’s Disease Medication Side Effects During Daily Activities https://ClinicalTrials.gov/show/NCT01429207 Completed Great Lakes NeuroTechnologies Inc. NA
NCT01338662 Comparison of the Incidence of Dyskinesia in Parkinson`s Disease Who Were Treated With Amantadine or Dopamine Agonist https://ClinicalTrials.gov/show/NCT01338662 Recruiting Seoul National University Hospital 2020-04-30
NCT04296539 Compare the Scapular Muscular Endurance, Scapular Stabilization, Scapular Dyskinesia and Postural Alignment Parameters of Female Individuals Between the Ages of 40-65 Living in the North Cyprus, Who Regularly Perform Pilates Exercise, With Adult Sedentary Individuals Between the Ages of 40-65 https://ClinicalTrials.gov/show/NCT04296539 Completed Cyprus International University 2019-06-27
NCT04161313 Respiratory Function, Exercise Capacity and Peripheral Muscle Strength Among Patients With CF, PCD and Healthy Children https://ClinicalTrials.gov/show/NCT04161313 Completed Bezmialem Vakif University 2020-02-24
NCT04064294 Preventing Levodopa Induced Dyskinesia in Parkinson’s Disease With HMG-CoA Reductase Inhibitors https://ClinicalTrials.gov/show/NCT04064294 Active, not recruiting VA Office of Research and Development 2022-12-31
NCT03801395 PCD New Gene Discovery https://ClinicalTrials.gov/show/NCT03801395 Active, not recruiting Vanderbilt University Medical Center 2020-07-01
NCT03704896 PRospective Observational Multicentre Study on VAriability of Lung Function in Stable PCD Patients https://ClinicalTrials.gov/show/NCT03704896 Active, not recruiting University of Southampton 2019-07-31
NCT03517865 International Primary Ciliary Dyskinesia Cohort https://ClinicalTrials.gov/show/NCT03517865 Recruiting University of Bern 2028-12-31
NCT03494894 Bacteriological Link Between Upper and Lower Airways in Cystic Fibrosis and Primary Ciliary Dyskinesia https://ClinicalTrials.gov/show/NCT03494894 Recruiting Centre Hospitalier Intercommunal Creteil 2019-09-01
NCT01246258 Otolith Function in Patients With Primary Ciliary Dyskinesia https://ClinicalTrials.gov/show/NCT01246258 Completed Imperial College Healthcare NHS Trust 2013-12-31
NCT00912977 Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia https://ClinicalTrials.gov/show/NCT00912977 Completed Oregon Health and Science University 2010-06-30
NCT00368446 Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease https://ClinicalTrials.gov/show/NCT00368446 Completed National Institutes of Health Clinical Center (CC) NA
NCT04453995 A Follow-up of the Influencing Factors of Dyskinesia in Patients With Parkinson’s Disease https://ClinicalTrials.gov/show/NCT04453995 Active, not recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 2021-12-31
NCT00783887 Diagnosis of Primary Ciliary Dyskinesia https://ClinicalTrials.gov/show/NCT00783887 Completed Assistance Publique - Hôpitaux de Paris 2012-12-31
NCT00722878 Long-term Lung Function and Disease Progression in Children With Early Onset Primary Ciliary Dyskinesia Lung Disease https://ClinicalTrials.gov/show/NCT00722878 Completed University of North Carolina, Chapel Hill 2019-08-31
NCT00608556 Dyskinesia, Heterotaxy and Congenital Heart Disease https://ClinicalTrials.gov/show/NCT00608556 Completed National Institutes of Health Clinical Center (CC) NA
NCT00467597 Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1) https://ClinicalTrials.gov/show/NCT00467597 Completed VA Office of Research and Development 2008-08-31
NCT00450918 Evaluating Progression of and Diagnostic Tools for Primary Ciliary Dyskinesia in Children and Adolescents https://ClinicalTrials.gov/show/NCT00450918 Completed University of North Carolina, Chapel Hill 2019-08-31
NCT00323167 Rare Genetic Disorders of the Breathing Airways https://ClinicalTrials.gov/show/NCT00323167 Completed University of North Carolina, Chapel Hill 2012-10-31
NCT00005650 Genetic Study of Patients With Primary Ciliary Dyskinesia https://ClinicalTrials.gov/show/NCT00005650 Completed National Center for Research Resources (NCRR) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03271840 Registry for Primary Ciliary Dyskinesia https://ClinicalTrials.gov/show/NCT03271840 Recruiting University of Alberta 2030-01-31
NCT02419365 International Primary Ciliary Dyskinesia (PCD) Registry https://ClinicalTrials.gov/show/NCT02419365 Recruiting University Hospital Muenster 2030-12-31
NCT04004949 the Effect of Scapular Dyskinesia on the Scapular Balance Angle & Upper Extremity Sensorimotor Function in Spastic Stroke Patient. The Patients Were Diagnosed With the Lateral Scapular Slide Test, Fugl-Meyer Upper Extremity (FMUE) Scale Scores & Scapular Balance Angle Test (SBA). https://ClinicalTrials.gov/show/NCT04004949 Completed October 6 University 2019-06-05
NCT03809091 WGS of Korean Idiopathic Bronchiectasis https://ClinicalTrials.gov/show/NCT03809091 Recruiting Seoul National University Hospital 2021-08-31
NCT03606200 Swiss Primary Ciliary Dyskinesia Registry https://ClinicalTrials.gov/show/NCT03606200 Recruiting University of Bern 2050-12-31